ClinicalTrials.gg
RecruitingNCT07626411ROXI-EVERESTUpdated Nov 18, 2026

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

A Phase 3 interventional study of REGN7508 and Apixaban in Atrial Fibrillation (AF), sponsored by Regeneron Pharmaceuticals. Recruiting at 84 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 18, 2026First sites in Japan and Canada54 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15,364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
15th of 679
15,364 · median 127
Started
2026
with 47 others
Phase 3
100 of 993
11 open now
Primary completion
2029-09
later than 194 of 219 live
Registered
981st of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 15th largest by planned enrollment of the 679 interventional ones that give a count, is one of 48 that started in 2026, is one of 100 in phase 3, reaches primary completion later than 194 of the 219 other live ones, and was the 981st registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 963 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 609 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.

The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
03

Conditions studied

  • Atrial Fibrillation (AF)

Keywords

  • Bleeding
  • Stroke
  • Systemic embolism
  • Blood clots
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
  2. Meets one of the following:

    1. CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
    2. CHA2DS2-VA score ≥3 OR
    3. CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
  3. Must have an (INR) \<2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)

Key Exclusion Criteria:

  1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
  2. Has known moderate-to-severe mitral stenosis
  3. Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
  4. Had an ischemic stroke within 2 days prior to randomization
  5. Has persistent, uncontrolled hypertension (per investigator's discretion)
  6. Has estimated (eGFR) \<15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15,364 participants (estimated)

Study arms

  • Experimental
    REGN7508 + Placebo

    Drug: REGN7508 · Drug: Placebo

  • Active comparator
    Apixaban + Placebo

    Drug: Apixaban · Drug: Placebo

Interventions

  • Administered per the protocol

    Also known as: cenvacibart

  • Administered per the protocol

  • DrugPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism

    Time frame: Approximately 36 months

  2. Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding

    Time frame: Approximately 36 months

Secondary outcomes

  1. Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding

    Time frame: Approximately 36 months

  2. Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding

    Time frame: Approximately 36 months

  3. Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death

    Time frame: Approximately 36 months

  4. Time to first occurrence of ISTH major bleeding

    Time frame: Approximately 36 months

  5. Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke

    Time frame: Approximately 36 months

  6. Time to occurrence of fatal bleeding

    Time frame: Approximately 36 months

  7. Number of ISTH major bleeding events

    Time frame: Approximately 36 months

  8. Number of ISTH CRNM bleeding events

    Time frame: Approximately 36 months

  9. Number of minor bleeding events

    Time frame: Approximately 36 months

  10. Time to all-cause death

    Time frame: Approximately 36 months

  11. Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Approximately 39 months

  12. Severity of TEAEs

    Time frame: Approximately 39 months

  13. Occurrence of Anti-Drug Antibodies (ADA) to REGN7508

    Time frame: Approximately 36 months

  14. Magnitude of ADA to REGN7508

    Time frame: Approximately 36 months

07

Study locations

84 of 84 sites recruiting
  • Advanced Cardiovascular
    Alexander City, Alabama 35010, United States
    Recruiting
  • SEC Clinical Research
    Dothan, Alabama 36305, United States
    Recruiting
  • Eastern Shore Research Institute
    Fairhope, Alabama 36532, United States
    Recruiting
  • West Valley Clinical Trials
    Glendale, Arizona 85306, United States
    Recruiting
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260, United States
    Recruiting
  • Arkansas Cardiology P.A.
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Valley Clinical Trials, Inc
    Covina, California 91723, United States
    Recruiting
  • Mission Cardiovascular Research Institute
    Fremont, California 94538, United States
    Recruiting
  • National Institute of California Heart and Vein Specialists
    Huntington Beach, California 92648, United States
    Recruiting
  • Alliance Clinical Los Angeles
    Inglewood, California 90301, United States
    Recruiting
  • Profound Research LLC at San Diego Cardiovascular Associates
    La Jolla, California 92037, United States
    Recruiting
  • Radin Cardiovascular Medical Group
    Newport Beach, California 92663, United States
    Recruiting
  • Valley Clinical Trials, LLC dba Flourish Research
    Northridge, California 91325, United States
    Recruiting
  • Southern California Heart Specialists
    Pasadena, California 91105, United States
    Recruiting
  • The Cardiovascular Center
    Redding, California 96001, United States
    Recruiting
  • FOMAT - Comprehensive Cardiovascular Care
    Santa Maria, California 93454, United States
    Recruiting
  • Cardiology Associates Medical Group
    Ventura, California 93003, United States
    Recruiting
  • Interventional Cardiology Medical Group
    West Hills, California 91307, United States
    Recruiting
  • Excel Medical Clinical Trials, dba Flourish Research
    Boca Raton, Florida 33434, United States
    Recruiting
  • Nouvelle Clinical Research LLC
    Cutler Bay, Florida 33189, United States
    Recruiting
  • Nature Coast Clinical Research - Inverness
    Inverness, Florida 34452, United States
    Recruiting
  • East Coast Institute for Research, Jacksonville
    Jacksonville, Florida 32216, United States
    Recruiting
  • South Florida Research Organization LLC
    Medley, Florida 33166, United States
    Recruiting
  • Novera Clinical Research
    Miami, Florida 33135, United States
    Recruiting
  • Healix Clinical Research
    New Smyrna Beach, Florida 32168, United States
    Recruiting
  • Sec Clinical Research
    Pensacola, Florida 32503, United States
    Recruiting
  • East Coast Institute for Research, St. Augustine
    Saint Augustine, Florida 32086, United States
    Recruiting
  • Flourish Research, St. Johns Center for Clinical Research
    Saint Augustine, Florida 32086, United States
    Recruiting
  • Cardiovascular Center of Sarasota Foundation for Research and Education
    Sarasota, Florida 34239, United States
    Recruiting
  • Clinical Site Partners, LLC DBA Flourish Research
    Winter Park, Florida 32789, United States
    Recruiting
  • Morehouse School Of Medicine
    Atlanta, Georgia 30310, United States
    Recruiting
  • Atlanta Clinical Research Centers
    Atlanta, Georgia 30342, United States
    Recruiting
  • NSC Research, Inc
    Johns Creek, Georgia 30024, United States
    Recruiting
  • Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
    Hobart, Indiana 46342, United States
    Recruiting
  • Franciscan Physician Network, Indiana Heart Physicians
    Indianapolis, Indiana 46237, United States
    Recruiting
  • Cardiovascular Research of Northwest Indiana, LLC
    Munster, Indiana 46321-4054, United States
    Recruiting
  • Profound Research, Powers Health Medical Group - Electrophysiology
    Munster, Indiana 46321, United States
    Recruiting
  • Monroe Research, LLC
    West Monroe, Louisiana 71291, United States
    Recruiting
  • Anderson Medical Research
    Ft. Washington, Maryland 20744, United States
    Recruiting
  • K2 Medical Research, Foxboro
    Foxborough, Massachusetts 02035, United States
    Recruiting
  • Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
    Bloomfield Hills, Michigan 48304, United States
    Recruiting
  • Profound Research, Millennium Cardiology
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Flint Clinical Research
    Flint, Michigan 48503, United States
    Recruiting
  • AA Medical Research Center (MRC)
    Flint, Michigan 48504, United States
    Recruiting
  • Super Health Pharmacy
    Staten Island, New York 10309, United States
    Recruiting
  • Hawthorne Health, Moose Pharmacy of Concord
    Concord, North Carolina 28025, United States
    Recruiting
  • Peters Medical Research
    High Point, North Carolina 27260, United States
    Recruiting
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
    Recruiting
  • K&R Research LLC
    Marion, Ohio 43302, United States
    Recruiting
  • Advanced Medical Research
    Maumee, Ohio 43537, United States
    Recruiting
  • Monument Health Clinical Research
    Rapid City, South Dakota 57701, United States
    Recruiting
  • Norwood Family Medicine
    Knoxville, Tennessee 37912, United States
    Recruiting
  • Tennessee Center for Clinical Trials
    Tullahoma, Tennessee 37388, United States
    Recruiting
  • PharmaTex Research
    Amarillo, Texas 79106, United States
    Recruiting
  • PanAmerican Clinical Research
    Brownsville, Texas 78520, United States
    Recruiting
  • Synergy Group Medical
    Houston, Texas 77036, United States
    Recruiting
  • Synergy Groups Medical
    Houston, Texas 77061, United States
    Recruiting
  • West Houston Area Clinical Trial Consultants, LLC
    Houston, Texas 77094, United States
    Recruiting
  • Texas Institute of Cardiology PA
    McKinney, Texas 75071, United States
    Recruiting
  • Synergy Group Medical, LLC
    Missouri City, Texas 77459, United States
    Recruiting
  • Permian Research Foundation
    Odessa, Texas 79761, United States
    Recruiting
  • Tyler Cardiovascular Consultants
    Tyler, Texas 75701, United States
    Recruiting
  • Alpine Research TC
    Clinton, Utah 84015, United States
    Recruiting
  • Boeson Research PVU
    Provo, Utah 84604, United States
    Recruiting
  • Carient Heart & Vascular
    Manassas, Virginia 20109, United States
    Recruiting
  • Conquest Research
    Vienna, Virginia 22182, United States
    Recruiting
  • Premiere Clinical Trial Network
    Hamilton, Ontario L8L 5G4, Canada
    Recruiting
  • Heart Health Institute Research Inc.
    Scarborough Village, Ontario M1B 4Z8, Canada
    Recruiting
  • Diex Recherche Inc.
    Sherbrooke, Quebec J1LOK3, Canada
    Recruiting
  • Viacar Recherches Cliniques inc.
    Longueuil, J4H4B9, Canada
    Recruiting
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital
    Nagoya, Aichi-ken 466-8650, Japan
    Recruiting
  • Uwajima City Hospital
    Uwajima, Ehime 798-8510, Japan
    Recruiting
  • Onga Nakama Medical Association Onga Hospital
    Onga District, Fukuoka 811-4342, Japan
    Recruiting
  • Gifu Prefectural General Medical Center - Main Hospital Building
    Gifu, Gifu 500-8717, Japan
    Recruiting
  • Hanaoka Seishu Memorial Hospital
    Sapporo, Hokkaido 062-0003, Japan
    Recruiting
  • The Veritas Hospital
    Kawanishi, Hyōgo 666-0125, Japan
    Recruiting
  • National Hospital Organization Mito Medical Center
    Higashiibaraki District, Ibaraki 311-3193, Japan
    Recruiting
  • National Hospital Organization Kasumigaura Medical Center
    Tsuchiura, Ibaraki 300-8585, Japan
    Recruiting
  • Saiseikai Yokohama-shi Nanbu Hospital
    Yokohama, Kanagawa 234-0054, Japan
    Recruiting
  • Rakuwakai Otowa Hospital
    Kyoto, Kyoto 607-8062, Japan
    Recruiting
  • Shizuoka City Shizuoka Hospital, East Building
    Shizuoka, Shizuoka 420-8630, Japan
    Recruiting
  • Minamino Cardiovascular Hospital
    Hachiōji, Tokyo 192-0918, Japan
    Recruiting
  • NewHeart Watanabe International Hospital
    Suginami Ward, Tokyo 168-0065, Japan
    Recruiting
  • JA Tsuchiura Kyodo General Hospital
    Kanagawa, Yokohama-shi 247-0005, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Sep 2029, 37 months after the start.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartActual
Aug 10, 2026
Primary completionEst.
Sep 11, 2029
CompletionEst.
Dec 10, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
54 sites added, 2 sites removed — first sites in Japan and Canada
Show 54 added (36 United States, 14 Japan, 4 Canada)
  • National Institute of California Heart and Vein Specialists · Huntington Beach, United States
  • Healix Clinical Research · New Smyrna Beach, United States
  • Eastern Shore Research Institute · Fairhope, United States
  • Arkansas Cardiology P.A. · Little Rock, United States
  • FOMAT - Comprehensive Cardiovascular Care · Santa Maria, United States
  • South Florida Research Organization LLC · Medley, United States
  • Flourish Research, St. Johns Center for Clinical Research · Saint Augustine, United States
  • Clinical Site Partners, LLC DBA Flourish Research · Winter Park, United States
  • Cardiovascular Research of Northwest Indiana, LLC · Munster, United States
  • Peters Medical Research · High Point, United States
  • Tyler Cardiovascular Consultants · Tyler, United States
  • Alpine Research TC · Clinton, United States
  • Rakuwakai Otowa Hospital · Kyoto, Japan
  • Scottsdale Clinical Trials · Scottsdale, United States
  • Excel Medical Clinical Trials, dba Flourish Research · Boca Raton, United States
  • Nature Coast Clinical Research - Inverness · Inverness, United States
  • Advanced Medical Research · Maumee, United States
  • K2 Medical Research Providence · East Providence, United States
  • Diex Recherche Inc. · Sherbrooke, Canada
  • Hanaoka Seishu Memorial Hospital · Sapporo, Japan
  • The Veritas Hospital · Kawanishi, Japan
  • Saiseikai Yokohama-shi Nanbu Hospital · Yokohama, Japan
  • West Valley Clinical Trials · Glendale, United States
  • Valley Clinical Trials, Inc · Covina, United States
  • Alliance Clinical Los Angeles · Inglewood, United States
  • Morehouse School Of Medicine · Atlanta, United States
  • Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic · Hobart, United States
  • K2 Medical Research, Foxboro · Foxborough, United States
  • Flint Clinical Research · Flint, United States
  • Lillestol Research LLC · Fargo, United States
  • …and 24 more on the registry record
Show 2 removed
  • Sun City Clinical Research · Glendale, United States
  • K2 Medical Research Providence · East Providence, United States
across 5 updates, Sep 28, 2026 – Nov 18, 2026
Show all 5 updates
  1. Nov 18, 2026
    18 sites added
    Show 18 added (10 United States, 7 Japan, 1 Canada)
    • The Cardiovascular Center · Redding, United States
    • East Coast Institute for Research, Jacksonville · Jacksonville, United States
    • Novera Clinical Research · Miami, United States
    • East Coast Institute for Research, St. Augustine · Saint Augustine, United States
    • Franciscan Physician Network, Indiana Heart Physicians · Indianapolis, United States
    • AA Medical Research Center (MRC) · Flint, United States
    • Norwood Family Medicine · Knoxville, United States
    • Synergy Group Medical · Houston, United States
    • Texas Institute of Cardiology PA · McKinney, United States
    • Boeson Research PVU · Provo, United States
    • Heart Health Institute Research Inc. · Scarborough Village, Canada
    • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital · Nagoya, Japan
    • Uwajima City Hospital · Uwajima, Japan
    • Onga Nakama Medical Association Onga Hospital · Onga District, Japan
    • Gifu Prefectural General Medical Center - Main Hospital Building · Gifu, Japan
    • Shizuoka City Shizuoka Hospital, East Building · Shizuoka, Japan
    • Minamino Cardiovascular Hospital · Hachiōji, Japan
    • NewHeart Watanabe International Hospital · Suginami Ward, Japan
  2. Nov 5, 2026
    14 sites added, 2 sites removed
    Show 14 added (9 United States, 3 Japan, 2 Canada)
    • West Valley Clinical Trials · Glendale, United States
    • Valley Clinical Trials, Inc · Covina, United States
    • Alliance Clinical Los Angeles · Inglewood, United States
    • Morehouse School Of Medicine · Atlanta, United States
    • Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic · Hobart, United States
    • K2 Medical Research, Foxboro · Foxborough, United States
    • Flint Clinical Research · Flint, United States
    • Lillestol Research LLC · Fargo, United States
    • Monument Health Clinical Research · Rapid City, United States
    • Premiere Clinical Trial Network · Hamilton, Canada
    • Viacar Recherches Cliniques inc. · Longueuil, Canada
    • National Hospital Organization Mito Medical Center · Higashiibaraki District, Japan
    • National Hospital Organization Kasumigaura Medical Center · Tsuchiura, Japan
    • JA Tsuchiura Kyodo General Hospital · Kanagawa, Japan
    Show 2 removed
    • Sun City Clinical Research · Glendale, United States
    • K2 Medical Research Providence · East Providence, United States
    + 1 other change: verification date
  3. Oct 26, 2026
    9 sites added — first site in Canada
    Show 9 added (5 United States, 3 Japan, 1 Canada)
    • Scottsdale Clinical Trials · Scottsdale, United States
    • Excel Medical Clinical Trials, dba Flourish Research · Boca Raton, United States
    • Nature Coast Clinical Research - Inverness · Inverness, United States
    • Advanced Medical Research · Maumee, United States
    • K2 Medical Research Providence · East Providence, United States
    • Diex Recherche Inc. · Sherbrooke, Canada
    • Hanaoka Seishu Memorial Hospital · Sapporo, Japan
    • The Veritas Hospital · Kawanishi, Japan
    • Saiseikai Yokohama-shi Nanbu Hospital · Yokohama, Japan
  4. Oct 8, 2026
    11 sites added — first site in Japan
    Show 11 added (10 United States, 1 Japan)
    • Eastern Shore Research Institute · Fairhope, United States
    • Arkansas Cardiology P.A. · Little Rock, United States
    • FOMAT - Comprehensive Cardiovascular Care · Santa Maria, United States
    • South Florida Research Organization LLC · Medley, United States
    • Flourish Research, St. Johns Center for Clinical Research · Saint Augustine, United States
    • Clinical Site Partners, LLC DBA Flourish Research · Winter Park, United States
    • Cardiovascular Research of Northwest Indiana, LLC · Munster, United States
    • Peters Medical Research · High Point, United States
    • Tyler Cardiovascular Consultants · Tyler, United States
    • Alpine Research TC · Clinton, United States
    • Rakuwakai Otowa Hospital · Kyoto, Japan
    + 1 other change: verification date
  5. Sep 28, 2026
    2 sites added
    Show 2 added (2 United States)
    • National Institute of California Heart and Vein Specialists · Huntington Beach, United States
    • Healix Clinical Research · New Smyrna Beach, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07626411
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Aug 10, 2026
Primary completion
Sep 11, 2029 (estimated)
Completion
Dec 10, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenvacibart

Start the discussion